Anonymousabout 2 hours ago
The FDA has lost five senior officials—including its commissioner, two CDER directors, and two CBER directors—since January 2025, creating what former officials and industry observers describe as an unprecedented leadership vacuum at the agency responsible for approving drugs, vaccines, and biologics for 330 million Americans. The departures, driven by a combination of forced removals, political pressure, and internal dysfunction, have raised urgent questions about who is making critical drug safety decisions and whether the institutional knowledge required to protect public health can survive this level of turnover.